{"slug":"theranostic","tag":"theranostic","variants":["theranostic"],"description":"No description yet","count":4,"kinds":{"target":4},"related":[{"slug":"pet-target","tag":"pet-target","shared":2},{"slug":"stroma","tag":"stroma","shared":1}],"records":[{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","tldr":"GRPR is a hormone receptor abundant in early and hormone-sensitive prostate cancer, imaged and treated with bombesin-like radioligands."},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","tldr":"A protein on prostate cancer cells that lets doctors both see the cancer on a PET scan and hit it with a radioactive drug."},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","tldr":"FAP (fibroblast activation protein) sits on the cancer-associated fibroblasts that scaffold more than 90% of epithelial cancers and is almost absent from normal adult tissue. FAPI PET tracers therefore light up tumours with high contrast, including pancreatic, gastric and low-grade cancers where FDG PET is weak, and FAP-targeted radioligands are in development."},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","tldr":"Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care."}]}